Compare Aurobindo Pharma with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs LUPIN - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA LUPIN AUROBINDO PHARMA/
LUPIN
 
P/E (TTM) x 19.6 46.6 42.0% View Chart
P/BV x 4.2 4.3 98.8% View Chart
Dividend Yield % 0.2 0.5 49.2%  

Financials

 AUROBINDO PHARMA   LUPIN
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
LUPIN
Mar-20
AUROBINDO PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs830882 94.1%   
Low Rs527505 104.4%   
Sales per share (Unadj.) Rs333.9339.4 98.4%  
Earnings per share (Unadj.) Rs40.4-5.9 -678.6%  
Cash flow per share (Unadj.) Rs51.815.5 334.5%  
Dividends per share (Unadj.) Rs2.506.00 41.7%  
Dividend yield (eoy) %0.40.9 42.6%  
Book value per share (Unadj.) Rs237.1276.7 85.7%  
Shares outstanding (eoy) m585.91453.00 129.3%   
Bonus / Rights / Conversions ESOPESOP-  
Price / Sales ratio x2.02.0 99.4%   
Avg P/E ratio x16.8-116.6 -14.4%  
P/CF ratio (eoy) x13.144.8 29.2%  
Price / Book Value ratio x2.92.5 114.2%  
Dividend payout %6.2-100.9 -6.1%   
Avg Mkt Cap Rs m397,569314,201 126.5%   
No. of employees `00017.918.3 97.6%   
Total wages/salary Rs m25,84929,868 86.5%   
Avg. sales/employee Rs Th10,956.98,400.6 130.4%   
Avg. wages/employee Rs Th1,447.71,632.0 88.7%   
Avg. net profit/employee Rs Th1,324.3-147.2 -899.7%   
INCOME DATA
Net Sales Rs m195,636153,748 127.2%  
Other income Rs m1,5534,838 32.1%   
Total revenues Rs m197,189158,585 124.3%   
Gross profit Rs m39,51924,849 159.0%  
Depreciation Rs m6,6809,702 68.8%   
Interest Rs m2,6263,630 72.3%   
Profit before tax Rs m31,76716,355 194.2%   
Minority Interest Rs m274 692.3%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m-881-7,521 11.7%   
Tax Rs m7,26911,571 62.8%   
Profit after tax Rs m23,645-2,694 -877.7%  
Gross profit margin %20.216.2 125.0%  
Effective tax rate %22.970.8 32.3%   
Net profit margin %12.1-1.8 -689.8%  
BALANCE SHEET DATA
Current assets Rs m153,645154,132 99.7%   
Current liabilities Rs m120,42992,252 130.5%   
Net working cap to sales %17.040.2 42.2%  
Current ratio x1.31.7 76.4%  
Inventory Days Days13582 164.7%  
Debtors Days Days64129 49.3%  
Net fixed assets Rs m103,90989,082 116.6%   
Share capital Rs m586906 64.7%   
"Free" reserves Rs m138,322124,461 111.1%   
Net worth Rs m138,908125,367 110.8%   
Long term debt Rs m1,80017,933 10.0%   
Total assets Rs m264,544249,839 105.9%  
Interest coverage x13.15.5 237.9%   
Debt to equity ratio x00.1 9.1%  
Sales to assets ratio x0.70.6 120.2%   
Return on assets %9.90.4 2,651.0%  
Return on equity %17.0-2.1 -792.2%  
Return on capital %23.88.7 273.1%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31651,450 189.1%   
Fx outflow Rs m40,58919,470 208.5%   
Net fx Rs m56,72731,980 177.4%   
CASH FLOW
From Operations Rs m16,22014,688 110.4%  
From Investments Rs m-28,76811,070 -259.9%  
From Financial Activity Rs m19,191-8,906 -215.5%  
Net Cashflow Rs m6,65616,853 39.5%  

Share Holding

Indian Promoters % 54.1 46.6 116.1%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 8.0 11.3 70.4%  
FIIs % 27.7 31.9 86.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.1 101.0%  
Shareholders   69,601 98,259 70.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Zoomed 613 Points Today(Closing)

Indian share markets extended gains as the session progressed and ended on a strong note.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 18, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS